747 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Nilsine Partners LLC

Nilsine Partners LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 747 shares of the medical research company’s stock, valued at approximately $233,000.

A number of other institutional investors have also recently made changes to their positions in AMGN. Vanguard Group Inc. boosted its position in Amgen by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 52,088,210 shares of the medical research company’s stock valued at $14,809,720,000 after buying an additional 3,045,657 shares during the period. Capital International Investors boosted its holdings in shares of Amgen by 547.8% during the first quarter. Capital International Investors now owns 7,005,269 shares of the medical research company’s stock worth $1,991,738,000 after purchasing an additional 5,923,915 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Amgen by 3.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,564,710 shares of the medical research company’s stock worth $1,890,769,000 after purchasing an additional 243,720 shares during the last quarter. Royal Bank of Canada increased its holdings in Amgen by 14.8% during the 4th quarter. Royal Bank of Canada now owns 5,831,624 shares of the medical research company’s stock valued at $1,679,625,000 after purchasing an additional 751,947 shares during the period. Finally, Norges Bank bought a new position in Amgen during the 4th quarter valued at approximately $1,556,912,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.9 %

Amgen stock traded up $2.82 during trading hours on Friday, hitting $333.83. The stock had a trading volume of 2,173,548 shares, compared to its average volume of 1,935,877. The stock’s 50-day moving average price is $324.99 and its 200-day moving average price is $300.78. The stock has a market capitalization of $179.38 billion, a P/E ratio of 47.69, a price-to-earnings-growth ratio of 2.96 and a beta of 0.58. Amgen Inc. has a 12-month low of $248.38 and a 12-month high of $346.85. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. During the same quarter in the previous year, the firm earned $5.00 earnings per share. Amgen’s revenue was up 20.1% on a year-over-year basis. Equities research analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.70%. Amgen’s payout ratio is 128.57%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Argus lifted their price objective on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Mizuho boosted their price objective on shares of Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. Morgan Stanley dropped their target price on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research report on Thursday, July 11th. Royal Bank of Canada boosted their price target on shares of Amgen from $332.00 to $362.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $380.00 price objective (up from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Eleven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $326.89.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.